$BLLN

Lynch Thomas P. sold $2.0M of BLLN

Lynch Thomas P. (See Remarks) sold 20,000 shares of BillionToOne, Inc. (BLLN) at an average of $99.99 ($96.47–$101.41, $2.00M total) across 13 trades on 2026-09-08 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Lynch Thomas P.
Published Sep 10, 2026, 11:44 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 10, 2026, 11:50 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$BLLN
Neutral
medium confidence
Mentioned
$BLLN
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BLLNNeutralLow
01

Why it matters

The disclosed sale reduces insider ownership, which may be viewed as a bearish signal by some traders.

02

Market read

Primary insider sale news for a micro‑cap; modest trading relevance.

03

What to watch

Potential upcoming clinical data releases that may offset the negative signal.

Relevance 5/10Novelty 4/10Timing: post‑market 2026‑09‑08

Background

Form 4 filings disclose insider transactions; a 10b5-1 plan indicates pre‑arranged sales.

Company-level read

Ticker impact

$BLLNNeutralMedium confidence
Context

Officer Lynch Thomas P. sold $2.0M of BLLN shares via a 10b5-1 plan, reducing his stake to 700 shares.

Expected impact

Potential short-term pressure on BLLN price, limited to a few cents.

Evidence & confidence

Form 4 is a primary disclosure; $2M sale by an officer is material for a micro‑cap but unlikely to move the stock dramatically.

Market effects

Minimal impact on the broader biotech sector.

No significant regional effect.

Limited to investors tracking BLLN.

Counterpoint

The sale could be a routine liquidity event unrelated to fundamentals.

Key entities

  • BillionToOne, Inc.

    Biotech firm listed on NASDAQ under ticker BLLN.

  • Lynch Thomas P.

    Officer of BillionToOne, executing a pre‑arranged 10b5‑1 sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$BLLNMedAI 8/10

BillionToOne Stock (BLLN) Falls After Hours: Here's What's Driving the Move - BillionToOne (NASDAQ:BLLN)

BillionToOne (NASDAQ:BLLN) shares fell 28.12% in after-hours after reporting Q2 results. For the quarter ended June 30, 2026, revenue rose to $109.4M from $66.6M, net income was $8.1M ($0.15/share), and gross margin improved to 70%. The company kept 2026 revenue guidance of $450M to $465M and plans Unity Fetal Risk Screen (Aug. 17) and Northstar Origin (Sept. 1) launches.

$BLLNMedAI 8/10

Billiontoone (BLLN) – Research Analysts’ Recent Ratings Updates

BillionToOne (NASDAQ: BLLN) saw multiple analyst rating and target changes. Weiss Ratings upgraded BLLN to “sell (d+)” (from “sell (d)”) on 5/15 and reaffirmed “sell (d)” on 5/1. Guggenheim raised its target to $120 (from $100) and kept a “buy” on 5/13. JPMorgan lifted its target to $125 and maintained “overweight” on 5/7. BTIG cut its target to $130 (from $140) while keeping “buy” on 5/7.

$DELLLow

Silver Lake Partners V DE (AIV), L.P. (Durban Egon) sold $14.9M of DELL (indirect holdings)

Silver Lake Partners V DE (AIV), L.P. sold 26,990 indirectly-held shares of Dell Technologies Inc. (DELL) at an average of $552.79 ($542.78–$564.46, $14.92M total) across 22 trades on 2026-09-15. Filed jointly with Silver Lake Technology Associates V, L.P. (Director), SLTA V (GP), L.L.C. (Director), Silver Lake Group, L.L.C. (Director) and Durban Egon (Director).